Maintenance therapy with certolizumab pegol for Crohn's disease

New England Journal of Medicine

Volumn 357, Issue 3, 2007, Pages 239-250

  Schreiber, Stefan ^a,h   Khaliq Kareemi, Mani ^b   Lawrance, Ian C ^c   Thomsen, Ole Østergaard ^d   Hanauer, Stephen B ^e   McColm, Juliet ^f   Bloomfield, Ralph ^f   Sandborn, William J ^g  

^a UNIVERSITY OF KIEL   (Germany)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f UCB PHARMA   (Belgium)

^g MAYO CLINIC   (United States)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISOLONE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROHN DISEASE; CYST; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HUMAN; IMMUNOPATHOLOGY; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; IRON DEFICIENCY ANEMIA; LOBAR PNEUMONIA; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OTITIS MEDIA; PELVIC INFLAMMATORY DISEASE; PERIANAL ABSCESS; PNEUMONIA; POLYP; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL GASTROENTERITIS;

EID: 34447515607     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa062897     Document Type: Article

References (22)

1. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
2. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
3. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339: 89-91.
4. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999;353:459-61.
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
7. Colombel JF, Sandborn WJ, Rutgeerts PJ, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
8. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
9. van den Brande JMH, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apopotosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-85.
10. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121: 1145-57.
11. Fossati G, Nesbitt AM. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab PEGOL (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol 2005; 100:Suppl:S298-S299. abstract.
12. Nesbitt AM, Henry AJ. High affinity and potency of the pegylated FAB' fragment CDP870 - a direct comparison with other anti-TNF agents. Am J Gastroenterol 2004;99:Suppl:S253. abstract.
13. Fossati G, Nesbitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). Am J Gastroenterol 2005;100: Suppl:S299. abstract.
14. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18. [Erratum, Gastroenterology 2005;129:1808.]
15. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
16. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
17. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41: 1133-7.
18. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
19. Koch GG, Gansky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J 1996;30:523-34.
20. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
21. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20: 1337-46.
22. Keystone E, Choy EH, Kalden J, Klareskog L, Sany J, Smolen J. CDP870, a novel, PEGylated, humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA). Arthritis Rheum 2001;44:2946.